Nanotechnology could enable test for early Alzheimer’s Disease


Scientists used nanotechnology to extract previously unseen blood signals of neurodegeneration in a mouse model of Alzheimer’s disease.

They say tests that capture early signs of neurodegeneration in blood offer enormous potential for those who suffer from the disease, as well as dementia patients, to receive effective treatment or manage their progressive condition before significant brain damage occurs.

Alzheimer’s disease can currently be diagnosed using brain scans only after someone has been showing behavioural symptoms, such as memory impairment.

By the time symptoms emerge, it is often too late to treat patients effectively.

Although early markers of the disease are believed to be present in blood, they exist in tiny numbers, making them difficult to detect.

But technology developed and patented by the Nanomedicine Lab at the University of Manchester allows low blood signals that could non-invasively describe the onset of Alzheimer’s disease to be magnified and analysed.


Source link

Related posts